-- The companies will continue to collaborate in the Australian market

Canopy Growth Corporation (TSX:WEED, NYSE:CGC) ("Canopy Growth") has sold its 
42,087,639 shares in Australian cannabis company AusCann Group Holdings 
(AusCann) via an off market block trade at $0.15 per share for gross proceeds 
of $6.3 million. The trade was facilitated by Canaccord Australia.

The sale represents Canopy Growth's total 13.2% interest in AusCann. 

"Canopy Growth remains optimistic about the future of the Australian medical 
cannabis market and will continue to collaborate with the team at Auscann to 
support greater physician understanding and patient access to high quality 
cannabis products throughout Australia," said Mark Zekulin, CEO, Canopy Growth. 
"The decision to divest our position in AusCann, which we obtained three years 
ago in exchange for support provided, will allow us to sharpen our focus on our 
wholly-owned operations in the market, while continuing to collaborate with our 
partners at AusCann." 

Dr. Marcel Bonn-Miller, Canopy Growth's Global Senior Director of Clinical 
Science, will continue to sit on the AusCann Board of Directors to facilitate 
future collaboration. 

Here's to Future Growth.

Contact:
Caitlin O'Hara
Media Relations
Caitlin.Ohara@canopygrowth.com
+1 613-291-3239

Investor Relations
Tyler Burns
Tyler.Burns@canopygrowth.com
+1 855-558-9333 ext. 122

About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, 
hemp and cannabis device company, offering distinct brands and curated cannabis 
varieties in dried, oil and Softgel capsule forms, as well as medical devices 
through Canopy Growth's subsidiary, Storz & Bickel GMbH & Co. KG. From product 
and process innovation to market execution, Canopy Growth is driven by a 
passion for leadership and a commitment to building a world-class cannabis 
company one product, site and country at a time. Canopy Growth has operations 
in over a dozen countries across five continents.

Canopy Growth's medical division, Spectrum Therapeutics is proudly dedicated to 
educating healthcare practitioners, conducting robust clinical research, and 
furthering the public's understanding of cannabis, and has devoted millions of 
dollars toward cutting edge, commercializable research and IP development. 
Spectrum Therapeutics sells a range of full-spectrum products using its 
colour-coded classification Spectrum system as well as single cannabinoid 
Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across Canada under its award-winning 
Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand 
which has built a large and loyal following by focusing on quality products and 
meaningful customer relationships.

From our historic public listing on the Toronto Stock Exchange and New York 
Stock Exchange to our continued international expansion, pride in advancing 
shareholder value through leadership is engrained in all we do at Canopy 
Growth. Canopy Growth has established partnerships with leading sector names 
including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA 
Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation 
Brands, to name but a few. Canopy Growth operates eleven licensed cannabis 
production sites with over 4.7 million square feet of production capacity, 
including over one million square feet of GMP certified production space. For 
more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of 
the United States Private Securities Litigation Reform Act of 1995 and 
"forward-looking information" within the meaning of applicable Canadian 
securities legislation. Often, but not always, forward-looking statements and 
information can be identified by the use of words such as "plans", "expects" or 
"does not expect", "is expected", "estimates", "intends", "anticipates" or 
"does not anticipate", or "believes", or variations of such words and phrases 
or state that certain actions, events or results "may", "could", "would", 
"might" or "will" be taken, occur or be achieved. Forward-looking statements or 
information involve known and unknown risks, uncertainties and other factors 
which may cause the actual results, performance or achievements of Canopy 
Growth or its subsidiaries to be materially different from any future results, 
performance or achievements expressed or implied by the forward-looking 
statements or information contained in this news release. Examples of such 
statements include statements with respect to divesting shares. Risks, 
uncertainties and other factors involved with forward-looking information could 
cause actual events, results, performance, prospects and opportunities to 
differ materially from those expressed or implied by such forward-looking 
information, including the Company's ability to satisfy provincial sales 
contracts or provinces purchasing all cannabis allocated to them, and such 
risks contained in the Company's annual information form dated June 25, 2019 
and filed with Canadian securities regulators available on the Company's issuer 
profile on SEDAR at www.sedar.com. Although the Company believes that the 
assumptions and factors used in preparing the forward-looking information or 
forward-looking statements in this news release are reasonable, undue reliance 
should not be placed on such information and no assurance can be given that 
such events will occur in the disclosed time frames or at all. The 
forward-looking information and forward-looking statements included in this 
news release are made as of the date of this news release and the Company does 
not undertake an obligation to publicly update such forward-looking information 
or forward-looking information to reflect new information, subsequent events or 
otherwise unless required by applicable securities laws.

SOURCE: Canopy Growth Corporation